| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
51,230,000 |
| Market
Cap: |
96.31(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.88 - $1.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
85,987 |
| Total Buy Value |
$0 |
$0 |
$0 |
$85,958 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
124,313 |
| Total Sell Value |
$0 |
$0 |
$0 |
$167,105 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Concentra Merger Sub, Inc. |
10% Owner |
– – • |
2023-05-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
36,367,727 |
|
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-03 |
4 |
A |
$9,737.70 |
$97,377,000 |
I/I |
10,000 |
10,000 |
|
- |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-05-03 |
4 |
D |
$1.85 |
$9,805,161 |
I/I |
(5,300,087) |
0 |
|
- |
|
| Concentra Biosciences, Llc |
10% Owner |
– – • |
2023-05-03 |
4 |
A |
$9,737.70 |
$97,377,000 |
D/D |
10,000 |
10,000 |
|
- |
|
| Drapkin Kimberlee C |
President, CFO and Treasurer |
• – – |
2023-05-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(66,018) |
0 |
|
- |
|
| Karsen Perry A |
Director |
– • – |
2023-05-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,000) |
0 |
|
- |
|
| Murray Richard /ca/ |
Director |
– • – |
2023-05-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(188,778) |
1 |
|
- |
|
| Kamen Robert |
Director |
– • – |
2023-05-03 |
4 |
D |
$0.00 |
$0 |
I/I |
(33,875) |
0 |
|
- |
|
| Kamen Robert |
Director |
– • – |
2023-05-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(60,975) |
0 |
|
- |
|
| Murray Richard /ca/ |
Director |
– • – |
2023-04-04 |
4 |
AS |
$1.85 |
$72,572 |
D/D |
(39,228) |
188,779 |
|
1% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-03-14 |
4 |
B |
$1.02 |
$20,651 |
I/I |
20,286 |
5,300,087 |
1.5 |
77% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-03-13 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,214,100 |
|
88% |
|
| Tang Capital Partners Lp |
10% Owner |
– – • |
2023-03-13 |
4 |
B |
$0.99 |
$65,307 |
I/I |
65,701 |
5,279,801 |
1.5 |
88% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
S |
$1.12 |
$5,741 |
D/D |
(5,126) |
103,417 |
|
-62% |
|
| Cole Hugh M |
Chief Operating Officer |
• – – |
2023-01-10 |
4 |
S |
$1.12 |
$10,284 |
D/D |
(9,182) |
110,082 |
|
-62% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2023-01-10 |
4 |
S |
$1.12 |
$8,715 |
D/D |
(7,781) |
66,018 |
|
-62% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2023-01-10 |
4 |
S |
$1.12 |
$27,864 |
D/D |
(24,879) |
228,007 |
|
-62% |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2023-01-09 |
4 |
S |
$1.10 |
$4,575 |
D/D |
(4,159) |
108,543 |
|
-76% |
|
| Cole Hugh M |
Chief Operating Officer |
• – – |
2023-01-09 |
4 |
S |
$1.10 |
$8,197 |
D/D |
(7,452) |
119,264 |
|
-76% |
|
| Drapkin Kimberlee C |
CFO and Treasurer |
• – – |
2023-01-09 |
4 |
S |
$1.10 |
$6,947 |
D/D |
(6,315) |
73,799 |
|
-76% |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2023-01-09 |
4 |
S |
$1.10 |
$22,210 |
D/D |
(20,191) |
252,886 |
|
-76% |
|
| Cole Hugh M |
Chief Operating Officer |
• – – |
2022-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
126,716 |
|
- |
|
| Murray Richard /ca/ |
CEO and President |
• • – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
87,500 |
273,077 |
|
- |
|
| Cole Hugh M |
Chief Business Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
106,716 |
|
- |
|
| Trehu Elizabeth |
Chief Medical Officer |
• – – |
2022-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
112,702 |
|
- |
|
158 Records found
|
|
Page 1 of 7 |
|
|
